The required sample size was calculated based on conservative estimated success rates
(complete/nearly complete resolution of the target IH at W24 compared to baseline) of 10%
(placebo), 20% (for 1 mg/kg/day, 3 months), 30% (for 1 mg/kg/day, 6 months), 40% (for
3 mg/kg/day, 3 months) and 55% (for 3 mg/kg/day, 6 months). The maximum number (based
on recruitment rate) was 450 randomized patients, assuming that the IDMC would not
recommend sample size increase at interim analysis. The sample size was calculated to
achieve >98% power if the most efficacious regimen was chosen and 78.9% power, if the
second most efficacious regimen was chosen for an overall one-sided type I error rate of
α=0.005.